Late intervention with anti-BRAF V600E therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer

Endocrinology

Volumn 153, Issue 2, 2012, Pages 985-994

  Nehs, Matthew A ^a   Nucera, Carmelo ^b   Nagarkatti, Sushruta S ^a   Sadow, Peter M ^a   Morales Garcia, Dieter ^a   Hodin, Richard A ^a   Parangi, Sareh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; B RAF KINASE V600E; ONCOPROTEIN; PLX 4720; PROTEIN P53; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER CELL CULTURE; CANCER GRAFT; CELL CYCLE PROGRESSION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LUNG METASTASIS; MOUSE; NECK COMPRESSION; NECK METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SURVIVAL TIME; THYROID CANCER; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; RANDOM ALLOCATION; SULFONAMIDES; THYROID NEOPLASMS; WEIGHT LOSS;

EID: 84856112428     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1519     Document Type: Article

References (37)

1. Neff RL, Farrar WB, Kloos RT, Burman KD 2008 Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 37:525-538 (Pubitemid 351711678)
2. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464
3. Broome JT, Gauger PG, Miller BS, Doherty GM 2009 Anaplastic thyroid cancer manifesting as new-onset Horner syndrome. Endocr Pract 15:563-566
4. Pasieka JL 2003 Anaplastic thyroid cancer. Curr Opin Oncol 15:78-83 (Pubitemid 36135652)
5. Braga-Basaria M, Ringel MD 2003 Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88:1947-1960 (Pubitemid 36549861)
6. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A, Jones SJ 2007 Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 142:717-727; discussion 727-729
7. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15:319-327 (Pubitemid 40208912)
8. Xing M 2007 BRAF mutationin papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (Pubitemid 350294294)
9. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107:10649-10654
10. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44
11. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893
12. Nucera C, Goldfarb M, Hodin R, Parangi S 2009 Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 1795:152-161
13. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G 2008 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-3046 (Pubitemid 351723664)
14. Packer LM, East P, Reis-Filho JS, Marais R 2009 Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res 22:785-798
15. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA 2009 MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106:20411-20416
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB 2010 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
17. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G 2010 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95:450-455
18. Nucera C, Lawler J, Parangi S 2011 BRAFV600E and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res 71:2417-2422
19. Meireles AM, Preto A, Rocha AS, Rebocho AP,Máximo V, Pereira-Castro I, Moreira S, Feijão T, Botelho T, Marques R, Trovisco V, Cirnes L, Alves C, Velho S, Soares P, Sobrinho-Simões M 2007 Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid 17:707-715
20. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S 2009 A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19:1077-1084
21. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S 2011 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296-309
22. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
23. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ, Motesanib Thyroid Cancer Study G 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
24. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
25. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
26. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954 (Pubitemid 34716871)
27. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982
28. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, Mazzon E, Belfiore A, Vigneri R 2008 BRAF(V600E)mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205 (Pubitemid 351449739)
29. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238-4245 (Pubitemid 40775662)
30. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435
31. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R 2010 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-221
32. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430
33. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA 2011 Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene 30:3153-3162
34. Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P 2001 Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA 98:13138-13143 (Pubitemid 33051330)
35. Nucera C, Lawler J, Hodin R, Parangi S 2010 The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget 1:751-756
36. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D 2007 BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840-2843 (Pubitemid 47037399)
37. Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P 2009 The BRAFV600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 69:8317-8325